Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial)

Health Technology Assessment

Volumn 17, Issue 22, 2013, Pages 1-167

  Grant, A M ^a   Boachie, C ^a   Cotton, S C ^a   Faria, R ^b   Bojke, L ^b   Epstein, D M ^b   Ramsay, C R ^a   Corbacho, B ^b   Sculpher, M ^b   Krukowski, Z H ^c   Heading, R C ^d   Campbell, M K ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d DURHAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CIMETIDINE; DICYCLOVERINE; DIGESTIVE TRACT SPASMOLYTIC AGENT; DIMETICONE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

ARTICLE; BLOATING; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DYSPHAGIA; ECONOMIC EVALUATION; ESOPHAGUS DILATATION; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIATUS HERNIA; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT SAFETY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; SHORT FORM 36; STOMACH FUNDOPLICATION; SURGEON; SURGICAL MORTALITY; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GREAT BRITAIN; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POSTOPERATIVE COMPLICATIONS; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84878989979     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17220     Document Type: Article

References (82)

1. Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease-a UK collaborative study. The REFLUX trial. Health Technol Assess 2008;12(31).
2. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ 2008;337:a2664. http://dx.doi.org/10.1136/bmj.a2664
3. Epstein D, Bojke L, Sculpher MJ, REFLUX trial group. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 2009;339:b2576. http://dx.doi.org/10.1136/bmj.b2576
4. Macran S, Wileman S, Barton G, Russell I. The development of a new measure of quality of life in the management of gastro-oesophageal reflux disease: the Reflux questionnaire. Qual Life Res 2007;16:331-43. http://dx.doi.org/10.1007/s11136-006-9005-3
5. Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics 2007;25:829-41. http://dx.doi.org/10.2165/00019053-200725100-00003
6. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20. http://dx.doi.org/10.1111/j.1572-0241.2006.00630.x
7. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56. http://dx.doi.org/10.1016/S0016-5085(97)70025-8
8. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-94. http://dx.doi.org/10.1046/j.1365-2036.2000.00884.x
9. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol 1999;34:3-8.
10. Davis CS, Baldea A, Johns JR, Joehl RJ, Fisichella PM. The evolution and long-term results of laparoscopic antireflux surgery for the treatments of gastroesophageal reflux disease. JSLS 2010;13:332-41. http://dx.doi.org/10.4293/108680810X12924466007007
11. Peters MJ, Mukhtar A, Yunus RM, Khan S, Pappalardo J, Memon B, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol 2009;104:1548-61. http://dx.doi.org/10.1038/ajg.2009.176
12. Donahue PE, Larson GM, Stewardson RH, Bombeck CT. Floppy Nissen fundoplication. Rev Surg 1977;34:223-4.
13. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. Ann Surg 1986;204:9-19. http://dx.doi.org/10.1097/00000658-198607000-00002
14. Broeders JAJL, Mauritz FA, Ahmed Ali U, Draaisma WA, Ruurda JP, Gooszen HG, et al. Systematic review and meta-analysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal reflux disease. Br J Surg 2010;97:1318-30. http://dx.doi.org/10.1002/bjs.7174
15. Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engstrom C, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009;7:1292-8. http://dx.doi.org/10.1016/j.cgh.2009.05.021
16. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology 1997;112:1798-810. http://dx.doi.org/10.1053/gast.1997.v112.pm9178669
17. Boutet R, Wilcock M, Mackenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999;13:813-17. http://dx.doi.org/10.1046/j.1365-2036.1999.00524.x
18. McCullagh M, Brown C, Bell D, Powell K. Long term acid suppressing treatment survey shows variation in practice. BMJ 1994;308:1238. http://dx.doi.org/10.1136/bmj.308.6938.1238
19. Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ. Long term acid suppressing treatment in general practice. BMJ 1994;308:827-30. http://dx.doi.org/10.1136/bmj.308.6932.827
20. Dibley LB, Norton C, Jones R. Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care. Br J Gen Pract 2010;60:e459-65. http://dx.doi.org/10.3399/bjgp10X544050
21. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995;9:137-43. http://dx.doi.org/10.1111/j.1365-2036.1995.tb00362.x
22. Bashford JNR, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of the link between morbidity and prescribing in the General Practice Research Database. BMJ 1998;317:452-6. http://dx.doi.org/10.1136/bmj.317.7156.452
23. Yang Y, Metz DC. Reviews in basic and clinical gastroenterology and hepatology safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-27. http://dx.doi.org/10.1053/j.gastro.2010.08.023
24. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931-50. http://dx.doi.org/10.1007/s10620-010-1560-3
25. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010;49:509-33. http://dx.doi.org/10.2165/11531320-000000000-00000
26. Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 1993;307:714-17. http://dx.doi.org/10.1136/bmj.307.6906.714
27. Cooper KG, Grant AM, Garratt AM. The impact of using a partially randomised patient preference design when evaluating alternative managements for heavy menstrual bleeding. Br J Obstet Gynaecol 1997;104:1367-73. http://dx.doi.org/10.1111/j.1471-0528.1997.tb11005.x
28. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ 1989;299:313-15. http://dx.doi.org/10.1136/bmj.299.6694.313
29. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 52, September 2006. London: BMA and RPS; 2006.
30. Torgerson D, Sibbald B. Understanding controlled trials: what is a patient preference trial? BMJ 1998;316:360. http://dx.doi.org/10.1136/bmj.316.7128.360
31. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999;44:S1-16.
32. Edwards PJ, Roberts IG, Clarke MJ, DiGuiseppi C, Wentz R, Kwan I, et al. Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev 2007;2:MR000008.
33. Brealey S, Atwell C, Bryan S. Improving response rates using monetary incentives for patient completion of questionnaires: an observational study. BMC Med Res Methodol 2007;7:12. http://dx.doi.org/10.1186/1471-2288-7-12
34. Kenyon S, Pike K, Jones D, Taylor D, Salt A, Marlow N, et al. The effect of a monetary incentive on return of a postal health and development questionnaire: a randomised trial. BMC Health Serv Res 2007;5:55. http://dx.doi.org/10.1186/1472-6963-5-55
35. Dirmaier J, Harfst T, Koch U, Schulz H. Incentives increased return rates but did not influence partial nonresponse or treatment outcome in a randomized trial. J Clin Epidemiol 2007;60:1263-70. http://dx.doi.org/10.1016/j.jclinepi.2007.04.006
36. Brooks R, with the EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. http://dx.doi.org/10.1016/0168-8510(90)90421-9
37. Jenkinson C, Layte R, Wright L, Coulter A. The UK SF-36: an analysis and interpretation manual. Oxford: Health Services Research Unit; 1996.
38. Nagelkerke N, Fidler V, Bersen R, Borgdorff M. Estimating treatment effects in randomised clinical trials in the presence of non-compliance. Stat Med 2000;19:1849-64. http://dx.doi.org/10.1002/1097-0258(20000730)19:14<1849::AID-SIM506>3.0.CO;2-1
39. White IR. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005;14:327-47. http://dx.doi.org/10.1191/0962280205sm406oa
40. Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, Ramsay CR, et al. Contamination in trials of educational interventions. Health Technol Assess 2007;11(43).
41. Fielding S, Fayers P, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. Health Qual Life Outcomes 2009;7:57. http://dx.doi.org/10.1186/1477-7525-7-57
42. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998;316:285. http://dx.doi.org/10.1136/bmj.316.7127.285
43. Wileman SM, McCann S, Grant AM, Krukowski ZH, Bruce J. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2010;3:CD003243.
44. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov 2006;13:238-49. http://dx.doi.org/10.1177/1553350606296389
45. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. Surg Endosc 2011;25:2547-54. http://dx.doi.org/10.1007/s00464-011-1585-5
46. Goeree R, Hopkins R, Marshall JK, Armstrong D, Ungar WJ, Goldsmith C, et al. Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: a 3-year prospective randomized controlled trial and economic evaluation. Value Health 2011;14:263-73. http://dx.doi.org/10.1016/j.jval.2010.09.004
47. Lundell L, Attwood S, Ell C, Fiocca R, Galmiche J, Hatlebakk J, et al. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008;57:1207-13. http://dx.doi.org/10.1136/gut.2008.148833
48. Galmiche J, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD. The LOTUS randomized clinical trial. JAMA 2011;305:1969-77. http://dx.doi.org/10.1001/jama.2011.626
49. Attwood SE, Lundell L, Hatlebakk JG, Eklund S, Junghard O, Galmiche J, et al. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646-55. http://dx.doi.org/10.1007/s11605-008-0645-1
50. Attwood SEA, Lundell L, Ell C, Galmiche J, Hatlebakk J, Fiocca R, et al. Standardization of surgical technique in antireflux surgery: the LOTUS trial experience. World J Surg 2008;32:995-8. http://dx.doi.org/10.1007/s00268-007-9409-4
51. Mahon D, Rhodes M, Decadt B, Hindmarsh A, Lowndes R, Beckingham I, et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg 2005;92:695-9. http://dx.doi.org/10.1002/bjs.4934
52. Cookson R, Flood C, Koo B, Mahon D, Rhodes M. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg 2005;92:700-6. http://dx.doi.org/10.1002/bjs.4933
53. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg 2006;10:1312-17. http://dx.doi.org/10.1016/j.gassur.2006.07.010
54. Wiklund I, Bigard MA, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD) 11. Eur J Surg 1998;164(Suppl. 583):41-9. http://dx.doi.org/10.1080/11024159850191238
55. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993;28(Suppl. 199):18-21. http://dx.doi.org/10.3109/00365529309098350
56. Rantanen TK, Salo JA, Sipponen JT. Fatal and life-threatening complications in antireflux surgery: analysis of 5502 operations. Br J Surg 1999;86:1573-7. http://dx.doi.org/10.1046/j.1365-2168.1999.01297.x
57. van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010;11:CD002095.
58. Romagnuolo J, Meier MA, Sadowski DC. Medical or surgical therapy for erosive reflux oesophagitis: cost-utility analysis using a Markov model. Ann Surg 2002;236:191-202. http://dx.doi.org/10.1097/00000658-200208000-00007
59. Arguedas MR, Heudebert GR, Klapow JC, Centor RM, Eloubeidi M, Wilcox CM. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol 2004;99:1023-8. http://dx.doi.org/10.1111/j.1572-0241.2004.30891.x
60. Comay D, Adam V, da Silveira EB, Kennedy W, Mayrand S, Barkun AN. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis. Can J Gastroenterol 2008;22:552-8.
61. HMSO Electronic Drug Tariff for the National Health Service of England and Wales. London: HMSO; 2010.
62. Manca A, Hawkins N. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96. http://dx.doi.org/10.1002/hec.944
63. Department of Health (DoH). NHS reference costs 2009-2010. London: DoH; 2010.
64. Curtis L. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2010.
65. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
66. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Discussion paper 138. York: Centre for Health Economics, University of York; 1995.
67. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3(10).
68. HM Treasury. Green book: appraisal and evaluation in central government. London: The Stationery Office; 2003.
69. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2010;30:377-99. http://dx.doi.org/10.1002/sim.4067
70. White IR, Mander A, Wason J, Bond S. Handling missing outcome data in randomised trials: a workshop for the Network of Hubs for Trials Methodology Research. Medical Research Council, Cambridge, 20 June 2011.
71. Royston P. Multiple imputation by the MICe system of chained equations. Implementation in Stata. J Stat Softw 2011;45(4). URL: www.jstatsoft.org (accessed 5 December 2012).
72. Little RJA, Rubin DB. Statistical analysis with missing data. New York, NY: Wiley; 1987.
73. Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: Wiley; 1987. http://dx.doi.org/10.1002/9780470316696
74. Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat 2007;61:79-90. http://dx.doi.org/10.1198/000313007X172556
75. Galati JC, Carlin JB, Royston P. MIM: Stata module to analyse and manipulate multiply imputed datasets. EconPapers. URL: http://EconPapers.repec.org/RePEc:boc:bocode:s456825 (accessed 1 July 2011).
76. Briggs AH, Gray A. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3(2).
77. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B 1964;2:211-43.
78. Burton A, Billingham LJ, Bryan S. Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data. Clin Trials 2007;4:154-61. http://dx.doi.org/10.1177/1740774507076914
79. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:910-12. http://dx.doi.org/10.1136/bmj.d40
80. Johannesson M, Weinstein S. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-67. http://dx.doi.org/10.1016/0167-6296(93)90005-Y
81. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(Suppl.):S68-80. http://dx.doi.org/10.1177/0272989X9801800209
82. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008;26:781-98. http://dx.doi.org/10.2165/00019053-200826090-00008